Literature DB >> 9292626

Discriminative-stimulus effects of clozapine in squirrel monkeys: comparison with conventional and novel antipsychotic drugs.

G J Carey1, J Bergman.   

Abstract

The effects of conventional and novel atypical antipsychotic drugs were compared to clozapine in squirrel monkeys that discriminated I.M. injections of clozapine (1.0 mg/kg) from saline in a two-lever drug discrimination procedure. Clozapine (0.03-3.0 mg/kg) produced dose-related increases in responding on the clozapine-associated lever with full substitution at the training dose in all monkeys. Dose-related increases in responding on the clozapine-associated lever and full substitution also were observed with structural analogues of clozapine including perlapine and fluperlapine (0.1-3.0 mg/kg), seroquel (0.1-5.6 mg/kg), and JL 5, JL 8 and JL 18 (0.1-3.0 mg/kg). Other clozapine analogues, including olanzapine, amoxapine, loxapine and clothiapine, and conventional antipsychotic drugs, including phenothiazines such as chlorpromazine and thioridazine, produced some clozapine-associated responding up to the highest doses that could be studied, but did not substitute for clozapine. Olanzapine did produce full clozapine-lever responding following pretreatment with the dopamine D2-receptor agonist (+)-PHNO (0.003-0.01 mg/kg). Putatively atypical antipsychotics that are structurally unrelated to clozapine including risperidone (0.003-0.1 mg/kg), sertindole (0.03-1.0 mg/kg) and remoxipride (0.1-5.6 mg/kg) similarly failed to substitute for clozapine up to the highest doses. The present results indicate that some, but not all, structural analogs of clozapine have clozapine-like discriminative-stimulus effects and that novel antipsychotic drugs which purportedly have clozapine-like clinical efficacy may not produce its interoceptive stimulus effects.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9292626     DOI: 10.1007/s002130050344

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  8 in total

Review 1.  Novel antipsychotics: issues and controversies. Typicality of atypical antipsychotics.

Authors:  E Stip
Journal:  J Psychiatry Neurosci       Date:  2000-03       Impact factor: 6.186

2.  Serotonin receptor mechanisms mediate the discriminative stimulus properties of the atypical antipsychotic clozapine in C57BL/6 mice.

Authors:  Scott D Philibin; Adam J Prus; Alan L Pehrson; Joseph H Porter
Journal:  Psychopharmacology (Berl)       Date:  2005-02-05       Impact factor: 4.530

3.  Further characterization of the discriminative stimulus properties of the atypical antipsychotic drug clozapine in C57BL/6 mice: role of 5-HT(2A) serotonergic and alpha (1) adrenergic antagonism.

Authors:  Scott D Philibin; D Matthew Walentiny; Sarah A Vunck; Adam J Prus; Herbert Y Meltzer; Joseph H Porter
Journal:  Psychopharmacology (Berl)       Date:  2008-11-07       Impact factor: 4.530

4.  Discriminative stimulus properties of the atypical antipsychotic clozapine and the typical antipsychotic chlorpromazine in a three-choice drug discrimination procedure in rats.

Authors:  Joseph H Porter; Adam J Prus; Robert E Vann; Stephen A Varvel
Journal:  Psychopharmacology (Berl)       Date:  2004-08-13       Impact factor: 4.530

Review 5.  Discriminative stimulus properties of atypical and typical antipsychotic drugs: a review of preclinical studies.

Authors:  Joseph H Porter; Adam J Prus
Journal:  Psychopharmacology (Berl)       Date:  2008-09-16       Impact factor: 4.530

6.  Characterization of the effects of receptor-selective ligands in rats discriminating the novel antipsychotic quetiapine.

Authors:  Andrew J Goudie; Judith A Smith; Mark J Millan
Journal:  Psychopharmacology (Berl)       Date:  2003-09-24       Impact factor: 4.530

Review 7.  What's in a name? The evolution of the nomenclature of antipsychotic drugs.

Authors:  Caroline King; Lakshmi N P Voruganti
Journal:  J Psychiatry Neurosci       Date:  2002-05       Impact factor: 6.186

8.  The DREADD agonist clozapine N-oxide (CNO) is reverse-metabolized to clozapine and produces clozapine-like interoceptive stimulus effects in rats and mice.

Authors:  Daniel F Manvich; Kevin A Webster; Stephanie L Foster; Martilias S Farrell; James C Ritchie; Joseph H Porter; David Weinshenker
Journal:  Sci Rep       Date:  2018-03-01       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.